Citadel Advisors’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-10,500
| Closed | -$349K | – | 11104 |
|
|
2020
Q2 | $349K | Buy |
+10,500
| New | +$334K | ﹤0.01% | 7671 |
|
|
2019
Q3 | – | Sell |
-14,600
| Closed | -$182K | – | 10049 |
|
|
2019
Q2 | $182K | Buy |
14,600
+4,100
| +39% | +$54.4K | ﹤0.01% | 8255 |
|
|
2019
Q1 | $153K | Buy |
10,500
+100
| +1% | +$1.28K | ﹤0.01% | 8380 |
|
|
2018
Q4 | $115K | Sell |
10,400
-19,500
| -65% | -$271K | ﹤0.01% | 8189 |
|
|
2018
Q3 | $786K | Buy |
+29,900
| New | +$808K | ﹤0.01% | 5953 |
|
|
2018
Q1 | – | Sell |
-17,000
| Closed | -$237K | – | 9027 |
|
|
2017
Q4 | $237K | Buy |
+17,000
| New | +$230K | ﹤0.01% | 6841 |
|
|
2016
Q4 | – | Sell |
-18,900
| Closed | -$221K | – | 8109 |
|
|
2016
Q3 | $221K | Buy |
+18,900
| New | +$222K | ﹤0.01% | 6173 |
|
|
2016
Q2 | – | Sell |
-16,500
| Closed | -$152K | – | 7653 |
|
|
2016
Q1 | $152K | Buy |
16,500
+11,900
| +259% | +$128K | ﹤0.01% | 5825 |
|
|
2015
Q4 | $68K | Buy |
4,600
+1,200
| +35% | +$20.1K | ﹤0.01% | 7062 |
|
|
2015
Q3 | $56K | Sell |
3,400
-6,200
| -65% | -$127K | ﹤0.01% | 7503 |
|
|
2015
Q2 | $219K | Sell |
9,600
-5,300
| -36% | -$106K | ﹤0.01% | 6201 |
|
|
2015
Q1 | $226K | Buy |
14,900
+2,100
| +16% | +$27.3K | ﹤0.01% | 6036 |
|
|
2014
Q4 | $154K | Sell |
12,800
-6,200
| -33% | -$70.9K | ﹤0.01% | 6267 |
|
|
2014
Q3 | $215K | Buy |
19,000
+10,800
| +132% | +$123K | ﹤0.01% | 5657 |
|
|
2014
Q2 | $99K | Buy |
8,200
+500
| +6% | +$5.91K | ﹤0.01% | 6240 |
|
|
2014
Q1 | $90K | Sell |
7,700
-2,700
| -26% | -$45.7K | ﹤0.01% | 6300 |
|
|
2013
Q4 | $184K | Buy |
10,400
+400
| +4% | +$6.72K | ﹤0.01% | 5112 |
|
|
2013
Q3 | $144K | Sell |
10,000
-1,400
| -12% | -$21.4K | ﹤0.01% | 5055 |
|
|
2013
Q2 | $172K | Buy |
+11,400
| New | +$150K | ﹤0.01% | 4797 |
|
Citadel Advisors's MNTA Position: Q4 2020 in Review
Citadel Advisors sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q4 2020, closing a stake of 836,737 shares — an estimated $43.9M sold.
Citadel Advisors first reported a position in MNTA in Q2 2013 and held it in 23 quarters. The position peaked at $58.7M in Q2 2020. 0 funds tracked by Wall St. Rank hold MNTA as of Q4 2020.
- Citadel Advisors reported no remaining Momenta Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
- Citadel Advisors sold 836,737 Momenta Pharmaceuticals, Inc. shares in Q4 2020, an estimated $43.9M.
- Citadel Advisors first reported a position in Momenta Pharmaceuticals, Inc. in Q2 2013 and held it in 23 quarters.
- Citadel Advisors's Momenta Pharmaceuticals, Inc. position peaked at $58.7M in Q2 2020.
- 0 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q4 2020.
Based on Citadel Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.